Navigation Links
NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting
Date:6/4/2011

er materially and adversely from these preliminary results; (iv) the timing or success of the commencement or end of clinical trials and commercial launch of new drugs may be delayed or unsuccessful due to commercial and funding considerations, regulatory delays, clinical trial design, slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical outcomes, or delay or failure in obtaining regulatory approval in one or more important markets; (v) the data from the NKTR-102 Phase 2 clinical study for breast cancer is not necessarily predictive of success in other cancer indications for which NKTR-102 is being studied (i.e. ovarian and colorectal cancers) or future success in Phase 3 clinical development that is currently planned to be conducted in metastatic breast cancer patients; (vi) the data package required and the timing for regulatory approval of a new drug application is very uncertain and difficult to predict due to broad regulatory discretion, changing standards of care, available approved therapies, the size of the completed clinical trials and the statistical significance of the results, the potential need for comparative clinical studies against approved therapies, and other important variables that are not within the control of Nektar; (vii) Nektar's patent applications for its proprietary or partner product candidates may not issue, patents that have issued may not be enforceable, or additional intellectual property licenses from third parties may be required in the future; (viii) the uncertain outcome of any future intellectual property, commercial or other litigation related to Nektar's proprietary product candidates, including without limitation NKTR-102; and (ix) certain other important risks and uncertainties set forth in Nektar's Quarterly Report on Form 10-Q for the quarter ended March 31, 2011, 2010, filed with the Securities and Exchange Commission on April 29, 2011.  Actual results
'/>"/>
SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
2. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
3. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
4. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
5. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
6. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
9. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
10. FDA Grants Orphan Drug Designation for Nektars Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
11. Nektar Announces New Phase 2 Data for NKTR-102 to Be Presented at 2011 ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014  Hologic, Inc. (NASDAQ: HOLX ), ... and Chief Executive Officer, will preside over the NASDAQ ... first day of Breast Cancer Awareness Month. In his ... on the important benefits of Hologic,s 3D Mammography technology, ... clinically superior to traditional mammography. This is ...
(Date:9/30/2014)... , Sept. 30, 2014 Arbor ... Summary Global Markets Direct,s, ,Arbor Pharmaceuticals, ... an overview of the Arbor Pharmaceuticals, LLC.,s pharmaceutical ... comprehensive information on the current therapeutic developmental pipeline ... at various stages, therapeutics assessment by drug target, ...
(Date:9/30/2014)... DALLAS , September 30, 2014 /PRNewswire/ ... market research report the "Glycobiology/Glycomics Market by Product ... Spectrometry, MALDI-TOF), Kits, and Reagents], Application (Immunology, ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, challenges, opportunities, current market trends, and ...
Breaking Medicine Technology:Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 2Hologic to Kick Off National Breast Cancer Awareness Month at the October 1 NASDAQ Stock Market Opening Bell Ceremony 3Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4
(Date:10/1/2014)... MI (PRWEB) October 01, 2014 To help ... wellness center , Cutler Integrative Medicine, is detailing several tips ... , According to Dr. Cutler, women should start ... quality time for yourself that will help ‘center’ yourself for ... of stress,” he says. , Other health and fitness ...
(Date:9/30/2014)... needs to be proactive about potential disease outbreaks like ... , In an Editorial in the October issue of ... , Allen Cheng from Monash University and Heath Kelly ... public health crises. , "Australia would do well to ... proactive in co-ordinating a consistent and outward looking response," ...
(Date:9/30/2014)... (HealthDay News) -- Children conceived either less than one year ... sibling could be at increased risk for autism, a new ... an outside expert agree that the research can,t prove that ... importantly, it is important that parents understand that the odds ... close together or far apart," said outside expert Dr. Andrew ...
(Date:9/30/2014)... Alan Mozes Health Day ... -- Colon cancer patients who are overweight or obese ... for developing a second weight-related cancer, new research suggests. ... of colon cancer recurrence, only the potential for developing ... that colorectal cancer survivors who reported being overweight or ...
(Date:9/30/2014)... Keystone Symposia will convene the first conference of its ... Health Series on "The Modes of Action of ... following the conclusion of the Grand Challenges Meeting for ... the Keystone Symposia Global Health Series, supported by the ... travel awards for 36 investigators from developing countries to ...
Breaking Medicine News(10 mins):Health News:In Recognition of National Women’s Health and Fitness Day, Cutler Integrative Medicine Details Tips for Living a Healthier and Happier Life 2Health News:Spacing Between Sibling Births Tied to Autism Risk in Study 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 2Health News:Obesity Tied to Higher Cancer Risk for Colon Cancer Survivors 3Health News:Keystone Symposia launches 2014-2015 meeting series with Global Health Vaccines Conference 2
... M&A activity in the,life sciences and healthcare sector is ... in 2008. CEOs, CFO,s and other business executives from,pharmaceutical, ... by some of the most sophisticated investors in the ... April 30-May 1, 2008,in Chicago., Deal volume in ...
... Simplifies Enrollment Process, SAN JOSE, Calif., Jan. ... the 47 million uninsured in America are,eligible for ... for Health Coverage Education (FHCE) has captured, on ... to,help people in need of health coverage., ...
... To Consumers Key Factor In Voter Opposition Compared To,Other ... than one,in five California voters (16%) support legislation, backed ... requires,proof of private health insurance when they are told ... according to a new poll., Overall, nearly two-thirds ...
... with popularity of hormone therapy, study finds , , WEDNESDAY, ... replacement therapy raise the risk of breast cancer in ... specific type of malignancy: lobular breast cancer. , The ... the January issue of Cancer Epidemiology, Biomarkers & ...
... that throughout this release there are hypnotic suggestions about why you ... you be able to pick out the suggestions? Or would they ... going on in the news, you came to the realization that ... to know unless you read on , In his fifth and ...
... with a Turn-Key Solution for Health Portal ... ... 16 HealthCare.com,( http://www.healthcare.com ), the leading healthcare provider directory and,online ... ( http://www.mediresource.com ), a leading creator and,syndicator of interactive health content ...
Cached Medicine News:Health News:Healthcare M&A Activity on the Rise 2Health News:Internet Comes to Rescue of 14 Million Uninsured in U.S.; Providing Access to Gov. Health Programs They're Not Aware of 2Health News:Internet Comes to Rescue of 14 Million Uninsured in U.S.; Providing Access to Gov. Health Programs They're Not Aware of 3Health News:New Poll: Only 16% of Californians Support Mandatory Purchase of Private Health Insurance; 71% Behind Regulation of Premium Increases 2Health News:HRT Raises Risk of Lobular Breast Cancer 2Health News:HRT Raises Risk of Lobular Breast Cancer 3Health News:Hypnotist ready to kick cigarette butt 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 2Health News:HealthCare.com & MediResource Partner to Distribute and License Health Content, Directory and Tools 3
Verte-Span is the latest advancement in vertebral body replacement technology. This device allows surgeons to reconstruct and stabilize certain types of anterior column defects in the spine....
... is indicated for use in the thoracolumbar spine ... or excised for the treatment of tumors, to ... neural tissues, and to restore the height of ... also indicated for treating fractures of the thoracic ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
Medicine Products: